5-oxo-5-[4-[1-[4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]pentylamino]phenyl]pentanoic acid
C25H26F3N3O4 — CID 157078299
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-oxo-5-[4-[1-[4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]pentylamino]phenyl]pentanoic acid
5-oxo-5-[4-[1-[4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]pentylamino]phenyl]pentanoic acid (PubChem CID 157078299) has the molecular formula C25H26F3N3O4 and a molecular weight of 489.49 g/mol. Its IUPAC name is 5-oxo-5-[4-[1-[4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]pentylamino]phenyl]pentanoic acid.
Molecular Properties
| Compound Name | 5-oxo-5-[4-[1-[4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]pentylamino]phenyl]pentanoic acid |
|---|---|
| PubChem CID | 157078299 |
| Molecular Formula | C25H26F3N3O4 |
| Molecular Weight | 489.49 g/mol |
| Exact Mass | 489.19 |
| IUPAC Name | 5-oxo-5-[4-[1-[4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]phenyl]pentylamino]phenyl]pentanoic acid |
| SMILES | CCCCC(Nc1ccc(C(=O)CCCC(=O)O)cc1)c1ccc(-c2nnc(C(F)(F)F)o2)cc1 |
| InChI | InChI=1S/C25H26F3N3O4/c1-2-3-5-20(29-19-14-12-17(13-15-19)21(32)6-4-7-22(33)34)16-8-10-18(11-9-16)23-30-31-24(35-23)25(26,27)28/h8-15,20,29H,2-7H2,1H3,(H,33,34) |
| InChIKey | ADFSOKNDYSPXDT-UHFFFAOYSA-N |
| XLogP | 6.54 |
| TPSA | 105.32 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 12 |
| Heavy Atoms | 35 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 489.49 |
| LogP ≤ 5 | 6.54 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 157078299 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.